证券之星消息，9月18日医疗美容板块较上一交易日下跌2.15%，华熙生物领跌。当日上证指数报收于 3831.66，下跌1.15%。深证成指报收于13075.66，下跌1.06%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.08 | -0.32% | 6.70万 | 2077.22万 | | 832982 | 锦波生物 | 298.48 | -0.41% | 6828.58 | 2.04亿 | | 300896 | 爱美客 | 186.61 | -1.74% | 4.52万 | 8.50亿 | | 688363 | 华熙生物 | 56.31 | -2.88% | 5.78万 | 3.28亿 | 从资金流向上来看，当日医疗美容板块主力资金净流出9636.81万元，游资资金净流入4312.4万元，散户 资金净流入5324.41万元。医疗美容板块个股资金流向见下表： | 代码 | | | 名称 | | | | | --- | --- ...

Core Insights - The 2025 CAME (2025 China Fragrance and Cosmetics Industry Annual Conference and Boutique Expo) marks a new era for China's fragrance and cosmetics industry, emphasizing high quality, high standards, and advanced technology [1][7] - The conference aims to create a platform for deep integration of government, industry, academia, research, and investment, promoting innovation and consumption trends in the industry [1][7] Event Overview - The event is scheduled from September 24 to 27, 2025, featuring multiple high-value meetings and activities focused on industry policy interpretation, technological innovation, brand building, and international cooperation [3] - The opening ceremony includes speeches from government leaders, international organization representatives, and industry leaders, launching the "Centennial Brand Renewal Plan" [3] Technological Innovation - The conference includes parallel sessions on technological innovation, such as discussions on global cosmetic regulatory trends and advancements in the implementation of the U.S. MoCRA [4] - Experts will analyze cutting-edge technologies like fullerene applications and synthetic biology in cosmetic ingredient manufacturing [4] Brand Development - The "2025 China Fragrance and Cosmetics Brand Value Conference" will release the "2025 China Fragrance and Cosmetics Brand Value Assessment Report," discussing pathways for domestic brands to break through cycles and reconstruct value [5] - Notable companies will showcase innovations in skincare technologies and concepts, highlighting the research capabilities and innovative vitality of domestic brands [5] Sustainability and Internationalization - The "2025 China Fragrance and Cosmetics Industry Sustainability (ESG) Forum" will present the "2025 China Fragrance and Cosmetics Industry Sustainability (ESG) Report," promoting green and low-carbon transformation in the industry [6] - The "Overseas Brand Global Strategy Exchange Conference" will provide practical insights for Chinese fragrance and cosmetics brands to enter global markets, focusing on EU market regulations and e-commerce strategies [6] Talent Development - The conference will address talent cultivation and industry ecosystem building, establishing a professional committee for talent development within the China Fragrance and Cosmetics Association [6] - Collaboration between universities and industry will be promoted through alumni events, facilitating the transformation of research outcomes and talent matching [6]

Core Viewpoint - Shanghai Haohai Biological Technology Co., Ltd. (688366.SH) is facing potential regulatory penalties due to insider trading allegations against its controlling shareholder Jiang Wei, although the company asserts that this matter will not significantly impact its operations or financials [1][3]. Group 1: Company Structure and Shareholding - Jiang Wei and his spouse You Jie are the actual controllers of Haohai Biological, holding a combined 45.82% of the company's shares as of March 2025, with Jiang Wei owning 28.53% and You Jie 17.29% [3]. - The regulatory penalty is directed solely at Jiang Wei, and the company clarifies that the issue is unrelated to its business operations [3]. Group 2: Business Overview and Financial Performance - Haohai Biological is a prominent producer of hyaluronic acid in China, operating in four main sectors: aesthetic medicine, ophthalmology, orthopedics, and hemostasis [3]. - In 2024, the revenue breakdown by product category shows that aesthetic medicine accounts for 44.30%, ophthalmic products 31.79%, and orthopedic products 16.92% [3]. - The ophthalmology segment is expected to see a revenue decline of 7.6% to 858 million yuan due to the impact of bulk procurement of artificial lenses [3]. - For the first half of 2025, the company reported a revenue of 1.304 billion yuan, a year-on-year decrease of 7.12%, and a net profit of 211 million yuan, down 10.29% year-on-year [3].

Core Viewpoint - The announcement regarding the administrative penalty against Jiang Wei, a controlling shareholder of Shanghai Haohai Biological Technology Co., Ltd., is significant as it stems from an insider trading investigation by the China Securities Regulatory Commission (CSRC) [1][2]. Group 1: Company Overview - Shanghai Haohai Biological Technology Co., Ltd. is a well-known hyaluronic acid producer in China, operating in four major fields: medical aesthetics, ophthalmology, orthopedics, and hemostasis [4]. - The company is recognized as one of the "three giants" in the Chinese hyaluronic acid market, alongside Huaxi Biological and Aimeike [4]. Group 2: Shareholding Structure - Jiang Wei and his spouse, You Jie, are the actual controllers of Haohai Biological, holding a combined 45.82% of the company's shares as of March 2025, with Jiang Wei owning 28.53% and You Jie 17.29% [4]. Group 3: Financial Performance - In the first half of 2025, the company reported a revenue of 1.304 billion yuan, a year-on-year decrease of 7.12%, and a net profit of 211 million yuan, down 10.29% year-on-year [5]. - For 2024, the revenue from the medical aesthetics segment is projected to account for 44.30% of total revenue, while ophthalmology products will contribute 31.79%, and orthopedics will make up 16.92% [4]. - The ophthalmology business is expected to see a revenue decline of 7.6% to 858 million yuan due to the impact of bulk procurement of artificial lenses [4].

Group 1 - The event "Exploring the Trillion-Yuan Biomanufacturing Synthesis Code" aims to showcase Shandong's biomanufacturing innovations and industry advantages, enhancing brand influence and accelerating new productivity development [1][4] - Shandong is recognized as a leader in biomanufacturing in China, with the most diverse product types and significant international standing [4][11] - The biomanufacturing industry in Shandong has achieved a unique advantage characterized by scale, complete supply chains, and active innovation, with several key products holding the world's largest production capacity [8][11] Group 2 - The provincial government plans to strengthen policy support and complete the "14th Five-Year" development plan for the biomanufacturing industry by the end of the year [8] - The industry is projected to exceed a production value of 680 billion yuan in 2024, with significant contributions to green products and carbon emission reductions [11] - Leading companies in the biomanufacturing sector, such as Huaxi Biotechnology Co., Ltd. and Shandong Bailong Chuangyuan Biotechnology Co., Ltd., shared their achievements and experiences during the event [16]

投资者可于 2025 年 09 月 19 日（星期五）至 09 月 25 日（星期四）16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 ir@bloomagebiotech.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 华熙生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 27 日发 布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半 年度经营成果、财务状况，公司计划于 2025 年 09 月 26 日（星期五）13:00-14:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 证券代码：688363 证券简称：华熙生物 公告编号：2025-035 华熙生物科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 09 月 26 ...

| 代码 | | | 名称 | | | | | --- | --- | --- | --- | --- | --- | --- | | 000615 *ST美谷 | -816.02万 | -34.93% | 325.27万 | 13.92% | 490.75万 | 21.01% | | 688363 华熙生物 | -2980.80万 | -12.87% | 1401.94万 | 6.05% | 1578.86万 | 6.82% | | 300896 爱美客 | -9072.07万 | -14.75% | 570.74万 | 0.93% | 8501.33万 | 13.82% | | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688363 | 华熙生物 | 57.98 | -0.77% | 3.99万 | | 2.32 Z | | 000615 | *ST美谷 | 3.09 | -1.28% | 7.53万 | | 2336.03万 | | 300896 | 爱美客 | 189. ...

Investment Rating - The report maintains an "Overweight" rating for the industry, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][28]. Core Insights - The report highlights significant market movements, with the retail trade, social services, and beauty care sectors showing varied performance, ranking 19th, 27th, and 25th respectively among 31 primary industries during the week of September 8-12, 2025 [14][16]. - Key events include Huaxi Biological's strategic investment in Saint Pharma, which focuses on small nucleic acid drugs, and Jinbo Biological's approval for a new injectable collagen product [3][23]. - The report notes a substantial increase in domestic and international flight searches ahead of the Mid-Autumn Festival and National Day holidays, indicating a recovery in travel demand [4][24]. Summary by Sections 1. Weekly Market Review - The retail trade sector increased by 0.85%, while social services and beauty care sectors decreased by 0.28% and 0.23% respectively, compared to the Shanghai Composite Index's increase of 1.52% [14][16]. 2. Key Industry Data and News - The Chinese government allocated 100 billion yuan for childcare subsidies and plans to gradually implement free preschool education [3][23]. - Huaxi Biological invested approximately 138 million HKD in Saint Pharma, acquiring a 9.44% stake, while Jinbo Biological's new collagen product is the first of its kind to enter the pharmaceutical excipient market [23][24]. 3. Key Company Announcements - Jinbo Biological announced management changes, with founder Yang Xia appointed as CEO, and plans for a cash acquisition by Langzi Co. for a controlling stake in a cosmetic surgery hospital [27][28]. 4. Investment Recommendations - The report recommends focusing on companies such as Shangmei Co., Juzi Biological, and Marumi Biological, among others, as potential investment opportunities in the beauty care and new consumption sectors [5][28].

Group 1: Retail Sales Performance - In August, China's retail sales grew by 3.4% year-on-year, with a month-on-month decline of 0.3 percentage points, continuing a slowdown since June [1] - The decline in national subsidy consumption categories is impacting retail sales growth, with various provinces controlling subsidy spending through measures like limiting daily subsidies and reducing eligible categories [1][2] - The overall expectation is for retail sales growth to continue to slow in the coming months, influenced by high base effects from the previous year [1] Group 2: Consumer Categories Analysis - The growth rates for various consumer categories in August were as follows: communication equipment +7.3%, furniture +18.6%, cultural and office supplies +14.2%, home appliances +14.3%, and daily necessities +7.7%, with future high base pressures anticipated [2] - The automotive sector showed weak demand, with traditional fuel vehicle prices declining, resulting in a year-on-year retail sales growth of only 0.8% for automobiles in August [2] - The food and beverage sector saw a year-on-year decline of 2.3% in tobacco and alcohol retail sales, while restaurant sales grew by 2.1% year-on-year, indicating a recovery in dining consumption [2] Group 3: Export Performance - In August, China's export scale reached $321.81 billion, with a year-on-year growth of 4.4% but a month-on-month decline of 2.8 percentage points [4] - The export growth to the United States continued to decline significantly, with a year-on-year decrease of 33.1% in August, which negatively impacted overall export growth by 5.1 percentage points [4]

Core Viewpoint - The Chinese beauty industry is experiencing a significant transformation driven by strategic investments in cutting-edge technology and content-driven brands, indicating a shift towards a more integrated and innovative market structure [4][25][28]. Investment Trends - In the first nine months of 2025, Chinese beauty companies completed 13 investments/acquisitions, with disclosed amounts exceeding 5.5 billion RMB, accounting for nearly 60% of the industry's capital flow [4][6]. - Major funding is concentrated in a few leading projects, indicating a selective investment phase, with the top three projects totaling nearly 5.2 billion RMB [6]. - The focus on technology and raw materials is evident, with regenerative medicine and RNA technology becoming key investment areas [7][24]. Strategic Investments - Huaxi Biological's investment in Saintno Pharmaceutical is a prime example of the focus on small nucleic acid drugs, which have significant potential despite the company currently lacking product sales [7][12]. - Proya's investment in Huazhi Xiao aims to build a business ecosystem, leveraging the brand's influence among young consumers and its potential for overseas expansion [10][13]. International Comparison - International giants like L'Oréal and Unilever are also active in the beauty investment space, with L'Oréal completing eight investments and Unilever seven in the first nine months of the year [14][19]. - The investment logic of international players tends to favor acquiring mature brands, while Chinese companies emphasize strategic collaboration and investment in technology [23][24]. Future Outlook - The current investment trends suggest a restructuring of the Chinese beauty industry, moving towards a model supported by technology, content, and global asset integration [25][30]. - The capital influx is raising industry standards, potentially eliminating smaller players lacking differentiation while providing growth opportunities for niche and innovative brands [24][25]. - The evolving landscape indicates that the future of the global beauty industry may be significantly influenced by the capital dynamics within China, potentially leading to the emergence of new world-class beauty giants from the Chinese capital ecosystem [30].